NEW ORLEANS — The potential mechanisms by which the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance, Lilly/Boehringer Ingelheim) may have reduced cardiovascular death in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback